Inclusion criteria encompassed patients with newly diagnosed localized IR and HR prostate cancer, Gleason score ≤ 7, clinical stage T1b to T3a, and PSA < 30 ng/mL. This evidence concerns the gene KLK3 and prostate carcinoma.